Mubucho (Dasatinib)

Dasatinib is a targeted tyrosine‑kinase inhibitor used in hematologic malignancies that involve the BCR‑ABL fusion protein.

• Chronic myeloid leukemia (chronic phase): reduces leukemic cell proliferation and improves survival.
• Chronic myeloid leukemia (accelerated or blast phase): provides disease control when resistance to first‑line therapy occurs.
• Philadelphia chromosome‑positive acute lymphoblastic leukemia: induces remission by inhibiting BCR‑ABL‑positive blasts.

• Dasatinib binds to the ATP‑binding site of BCR‑ABL and Src family tyrosine kinases, blocking their catalytic activity. This inhibition prevents downstream phosphorylation events that drive malignant cell growth, survival, and migration, leading to apoptosis of leukemic cells that depend on these signaling pathways.

Dasatinib may cause a range of adverse reactions, from mild to severe.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Diarrhea: watery stools, often transient.
• Fatigue: generalized tiredness.
• Rash: skin erythema or pruritus.
• Myelosuppression: reduced white blood cells, platelets, or neutrophils.
• Fluid retention: peripheral edema.

Serious or Rare Side Effects

• Pleural effusion: accumulation of fluid around the lungs.
• Pulmonary hypertension: elevated pressure in pulmonary arteries.
• Severe bleeding: gastrointestinal or intracranial hemorrhage.
• Cardiac dysfunction: decreased left‑ventricular ejection fraction.
• Hepatic toxicity: elevated liver enzymes or hepatitis.
• Severe infections: opportunistic bacterial, fungal, or viral infections.

When prescribing Dasatinib, clinicians should observe several safety measures.

• Monitor blood counts: perform complete blood count regularly to detect myelosuppression.
• Assess cardiac function: baseline ECG and periodic monitoring for pulmonary hypertension.
• Evaluate for pleural effusion: watch for dyspnea, cough, or chest discomfort.
• Avoid strong CYP3A4 inhibitors: concomitant use may increase dasatinib exposure.
• Store at ambient temperature: keep in the original container, protect from moisture and light.

Dasatinib interacts with several drug classes that may alter its efficacy or safety.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may raise plasma concentrations.
• Antacids containing aluminum or magnesium: reduce oral absorption of dasatinib.
• QT‑prolonging agents (e.g., sotalol, quinidine): increase risk of cardiac arrhythmias.

Moderate Interactions (Monitor Closely)

• Moderate CYP3A4 inhibitors (e.g., erythromycin, clarithromycin): require dose adjustment.
• CYP3A4 inducers (e.g., rifampin, carbamazepine): may lower dasatinib levels and reduce effectiveness.
• Warfarin: concurrent use may enhance anticoagulant effect and bleeding risk.